Sign In
Buy CSTL
$20.39
+0.680 (+3.45%)
At Close: Jun 03, 2026
Analysts Estimate Castle Biosciences, Inc. (CSTL) to Report a Decline in Earnings: What to Look Out for
11:06am, Monday, 27'th Oct 2025
Castle Biosciences (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FRIENDSWOOD, Texas, Oct. 26, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data dem
Castle is presenting data on DecisionDx®-Melanoma and its pipeline atopic dermatitis (AD) test at the 25th Annual Fall Clinical Dermatology Conference.
How Much Upside is Left in Castle Biosciences (CSTL)? Wall Street Analysts Think 50.08%
10:56am, Thursday, 23'rd Oct 2025
The consensus price target hints at a 50.1% upside potential for Castle Biosciences (CSTL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earning
What Makes Castle Biosciences (CSTL) a New Strong Buy Stock
01:01pm, Tuesday, 21'st Oct 2025
Castle Biosciences (CSTL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Castle Biosciences to Release Third Quarter 2025 Financial Results and Host Conference Call on Monday, Nov. 3, 2025
07:00am, Monday, 13'th Oct 2025
FRIENDSWOOD, Texas, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will
Castle Biosciences' Founder, President and CEO Derek Maetzold Honored with the CEO of the Year Award by The CEO Magazine
04:30pm, Wednesday, 01'st Oct 2025
FRIENDSWOOD, Texas, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its fou
Castle Biosciences Honored with a Greater Pittsburgh Top Workplaces 2025 Award
07:00am, Tuesday, 23'rd Sep 2025
FRIENDSWOOD, Texas, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it ha
Castle Biosciences Named One of Newsweek's America's Greatest Companies 2025
07:00am, Wednesday, 17'th Sep 2025
FRIENDSWOOD, Texas, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, has been included in the i
FRIENDSWOOD, Texas, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that new d
Castle Biosciences: Strong Margins, Solid Balance Sheet, And Big Upside Potential
09:14am, Tuesday, 02'nd Sep 2025
Castle Biosciences effectively translates complex diagnostics into a scalable, high-margin business, with strong clinical demand and a robust balance sheet supporting long-term growth. The investment
New validation study shows DecisionDx-SCC significantly outperforms current staging systems in predicting risk of local recurrence and metastasis for NCCN high-risk patients Clinician survey confirms
Castle Biosciences to Participate in Upcoming Investor Conferences
07:00am, Thursday, 21'st Aug 2025
FRIENDSWOOD, Texas, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its ex
Castle Biosciences, Inc. (CSTL) Q2 2025 Earnings Call Transcript
10:21pm, Monday, 04'th Aug 2025
Castle Biosciences, Inc. (NASDAQ:CSTL ) Q2 2025 Earnings Conference Call August 4, 2025 4:30 PM ET Company Participants Camilla Zuckero - Vice President of Investor Relations & Corporate Affairs Derek
Castle (CSTL) Q2 Revenue Tops Estimates
08:50pm, Monday, 04'th Aug 2025
Castle (CSTL) Q2 Revenue Tops Estimates
